“Throughout the first quarter of 2025 we have maintained strong and steady progress with our clinical program for efzofitimod in interstitial lung disease (ILD),” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “The program’s cornerstone is our Phase 3 EFZO-FIT(TM) study in pulmonary sarcoidosis, the most prevalent form of ILD for which no new treatments have been approved in more than 70 years. We look forward to reporting topline data from this study next quarter with the hopes of advancing standard of care beyond oral corticosteroids for sarcoidosis patients.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATYR:
- aTyr Pharma Stockholders Approve Key Proposals at Annual Meeting
- Promising Potential of aTyr Pharma’s ATYR2810 in Glioblastoma Treatment: Analyst Recommends Buy
- aTyr Pharma presents preclinical data on ATYR2810 at AACR
- Confident Buy Rating for aTyr Pharma Amidst Promising Phase 3 Study Insights
- aTyr names Dalia Reyes head of commercial, global efzofitimod franchise